share_log

Braxia Scientific to Present at H.C. Wainwright Global Investment Conference, Miami from May 24-26, 2022

Braxia Scientific to Present at H.C. Wainwright Global Investment Conference, Miami from May 24-26, 2022

布拉夏科学公司将出席2022年5月24日至26日在迈阿密举行的H.C.Wainwright全球投资会议
PR Newswire ·  2022/05/19 18:07

TORONTO, May 19, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Investment Conference from May 24 – 26, 2022 in Miami, Florida.

多伦多,2022年5月19日/美通社/-BraxiaScience Corp.(“Braxix”,或“公司”),(CSE:BRAX)(场外交易代码:BRAXF)(FWB:4960)是一家医疗研究公司,拥有为抑郁症和相关障碍患者提供创新性氯胺酮治疗的诊所,该公司高兴地宣布参加2022年5月24日至26日举行的H.C.Wainwright全球投资会议。佛罗里达州迈阿密.

Braxia Scientific CEO Dr. Roger McIntyre will present an overview of the Company's business, including its progress on increasing access to novel ketamine and psychedelic treatments for patients with depression and expanding the clinical research infrastructure required to execute on the Company's growing pipeline of registered clinical trials alongside third-party sponsors. Braxia's trials include Canada's first multi-dose psilocybin-assisted therapy trial which commenced in November 2021 and is expected to report preliminary results in the coming weeks. 

布拉夏科学公司首席执行官罗杰·麦金太尔博士将介绍该公司的业务概况,包括该公司在增加抑郁症患者获得新氯胺酮和迷幻疗法方面的进展,以及扩大临床研究基础设施,以与第三方赞助商一起执行该公司日益增长的注册临床试验管道。布拉夏的试验包括加拿大的首个多剂量裸盖菇素辅助治疗试验于2021年11月开始,预计将报告未来几周的初步结果。

Dr. McIntyre will also be available to host one-on-one meetings with institutional investors registered with H.C. Wainwright and Co.

麦金太尔博士还将主持与在H.C.Wainwright and Co.注册的机构投资者举行的一对一会议。

About Braxia Scientific Corp.

布拉夏科学公司简介

Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.

布拉夏科学公司是一家医学研究公司,拥有为抑郁症和相关疾病患者提供创新型氯胺酮治疗的诊所。通过其医疗解决方案,Braxia旨在减轻以大脑为基础的疾病的疾病负担,如严重的抑郁症等。Braxia主要专注于(I)拥有和经营多学科诊所,为精神健康障碍提供治疗,以及(Ii)与发现和商业化新药和给药方法有关的研究活动。布拉夏寻求从其知识产权开发平台开发氯胺酮及其衍生物和其他迷幻产品。通过其全资子公司加拿大卓越快速治疗中心公司,Bracia目前在密西索加经营着多学科社区诊所,为抑郁症提供快速有效的治疗,多伦多、渥太华和蒙特利尔.

ON BEHALF OF THE BOARD

我代表董事会

"Dr. Roger S. McIntyre"
Dr. Roger S. McIntyre

“罗杰·S·麦金太尔博士”
Dr。罗杰·S·麦金太尔

Chairman & CEO

董事长兼首席执行官

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

CSE未对本新闻稿的准确性或充分性进行审查,也不承担任何责任。

Forward-looking Information Cautionary Statement

前瞻性信息警示声明

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are "forward-looking statements."

本新闻稿包含符合适用证券法的前瞻性陈述。所有不是历史事实、未来估计、计划、计划、预测、预测、目标、假设、预期或对未来业绩的信念的陈述都是“前瞻性陈述”。

Forward-looking statements include statements about the intended promise of ketamine-based treatments for depression and the potential for ketamine to treat other emerging psychiatric disorders, such as Bipolar Depression. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the failure of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and engaging in activities that could be later determined to be illegal under domestic or international laws. Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the "CDSA") and it is a criminal offence to possess such substances under the CDSA without a prescription or a legal exemption. Health Canada has not approved psilocybin as a drug for any indication, however ketamine is a legally permissible medication for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without a prescription.

前瞻性陈述包括关于以氯胺酮为基础的抑郁症治疗的预期承诺,以及氯胺酮治疗其他新出现的精神障碍的可能性,如双相抑郁。此类前瞻性表述涉及已知和未知的风险、不确定性和其他因素,可能导致实际结果、事件或发展与此类前瞻性表述明示或暗示的任何未来结果、事件或发展大相径庭。除其他外,这些风险和不确定性包括氯胺酮、裸盖菇素和其他迷幻剂未能提供预期的健康益处和意想不到的副作用,依赖于获得和维持监管批准,包括获得和续签联邦、省、市、地方或其他许可证,以及从事后来根据国内或国际法可能被认定为非法的活动。氯胺酮和裸盖菇素目前分别是《受控药物和物质法》(《受控药物和物质法》,S.C.1996,c.19)规定的附表一和附表三的受控物质,根据《受控药物和物质法》,在没有处方或法律豁免的情况下拥有这类物质是刑事犯罪。加拿大卫生部尚未批准裸盖菇素作为任何适应症的药物,但氯胺酮是法律允许用于治疗某些心理疾病的药物。在中国拥有这种物质是违法的加拿大没有处方的话。

These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, including the Amended and Restated Listing Statement dated April 15, 2021, which are available at . There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.

这些因素应仔细考虑,并告诫读者不要过度依赖此类前瞻性陈述。尽管公司试图确定可能导致实际行动、事件或结果与前瞻性陈述中描述的大不相同的重要风险因素,但可能存在其他风险因素,导致行动、事件或结果与预期、估计或预期的不同。识别可能影响财务业绩的风险和不确定性的其他信息包含在公司提交给加拿大证券监管机构的文件中,包括日期为2021年4月15日的修订和重新发布的上市声明,这些文件可在以下网址查阅。不能保证前瞻性陈述将被证明是准确的,因为实际结果和未来事件可能与前瞻性陈述中预期的大不相同。

SOURCE Braxia Scientific Corp.

来源:布拉夏科学公司

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发